Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by CancerSlayeron Jun 11, 2022 4:16pm
387 Views
Post# 34749515

The Forgotten Chart…

The Forgotten Chart…From May 30 MD&A....

Just looking at the 450 day data for all evaluable patients (19) in Ph 2 only, 32% responded (6 of 19) & therefore 68% didn't respond (13 of 19).  For all 19 evaluable patients, the CR & PR rates were reported as 23% & 9%, respectively.  Although these percentages don't give rounded numbers (4.37 & 1.71), I'm assuming the number of CRs & PRs were 4 & 2, respectively.   

Responders (R)  = 6 patients
Non-responders (NR) = 13 patients  

Note:  Assuming a minimum 9 NRs came from the first 12 treated:

450 Days              Optimized Patients (7)              Non-optimized (12)

NR (range)                     4 to 1                                        9 to 12 

R (range)                        3 to 6                                        3 to 0

*RR (range)                  43% to 86%                             25% to 0%

**CRR (range)              57% to 14%                             25% to 0%

*  Response Rate
** Complete Response Rate


Note:  The above analysis is my interpretation only.  DYODD & GLTA...
<< Previous
Bullboard Posts
Next >>